Scarica l'app Stockscreener
1,251.61
3.55%
42.87
Dopo l'orario di chiusura:
1253.70
2.09
+0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
5 Stocks to Start With if You Only Have $1,000 - The Motley Fool
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Roche Expands Obesity Pipeline With Rona's RNAi Candidate - Zacks Investment Research
Stock Market Midday, Oct. 14: Hot Inflation Weighs on Markets, CoreWeave Plummets 15% - The Motley Fool
Eli Lilly and Co Stock (LLY) Opened Up by 3.70% on Oct 14: Key Drivers Unveiled - TradingKey
Eli Lilly schedules October 29 earnings as Eli Lilly stock sits 4.73 percent below its high - ad-hoc-news.de
4 High-Risk Stocks Built for Big Returns - The Motley Fool
A Look at Eli Lilly and Co (LLY) After 1.4% Decline -- GF Value $1575.10 vs Price $1166.51 - GuruFocus
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's Why Eli Lilly (LLY) Fell More Than Broader Market - Zacks Investment Research
Eli Lilly & Co. stock outperforms competitors despite losses on the day - MarketWatch
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years - The Motley Fool
BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades (XLV:NYSEARCA) - Seeking Alpha
AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades - TradingView
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar? - Zacks Investment Research
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. - The Motley Fool
Lilly Begins On $6.5B Houston Manufacturing Facility : CEG - Construction Equipment Guide
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Lilly seeks to provide $19.3M to Lebanon for expanded hazmat services - Inside INdiana Business
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
4 Healthcare Stocks Worth Owning for the Next Decade - The Motley Fool
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - Zacks Investment Research
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - The Motley Fool
Eli Lilly presented new trial data. Eli Lilly stock gains 1.09 percent - ad-hoc-news.de
Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next. - The Motley Fool
Eli Lilly says combining Taltz and Zepbound works better than Taltz alone in psoriasis study - MedWatch
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? - The Motley Fool
Eli Lilly Sued Over Alleged Digestive Complications From GLP-1 Medication - InkFreeNews.com
As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Legend Biotech (LEGN) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Eli Lilly-Backed Biotech TRex Dips 3.6% After $116.7 Million IPO - Bloomberg.com
Eli Lilly Lobs 4 Suits Alleging Illegal Weight Loss Drug Sales - Law360
Eli Lilly Says Weight Clinic 'Mocks' FDA With Illegal Drugs - Law360
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Yahoo Finance
3 Top-Ranked Healthcare Mutual Funds for a Defensive Portfolio - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Eli Lilly & Co (LLY) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. - The Motley Fool
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly sued over stomach problems patient ties to Mounjaro and Trulicity - Inside INdiana Business
0.25%
2.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):